title: BAFF levels in patients with ankylosing spondylitis and response to anti-tumor necrosis factor treatment.
authors.forename: Fabienne
authors.initials: F
authors.lastname: Niederer
authors.forename: Almut
authors.initials: A
authors.lastname: Scherer
authors.forename: Diego
authors.initials: D
authors.lastname: Kyburz
authors.forename: Renate E
authors.initials: RE
authors.lastname: Gay
authors.forename: Steffen
authors.initials: S
authors.lastname: Gay
authors.forename: Beat A
authors.initials: BA
authors.lastname: Michel
authors.forename: Adrian
authors.initials: A
authors.lastname: Ciurea
mesh_terms: D000068879:Adalimumab; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use; D053264:B-Cell Activating Factor / Q000097:blood*; D016022:Case-Control Studies; D006801:Humans; D012720:Severity of Illness Index; D013167:Spondylitis, Ankylosing / Q000097:blood* / Q000188:drug therapy*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D053264:B-Cell Activating Factor; C505719:TNFSF13B protein, human; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab